A Polyphenolic Complex Attenuates Inflammatory Response and Blood-Brain Barrier Disruption

被引：10

作者：

Bian, Yuting ^{[1
]}

Yamashita, Toru ^{[1
]}

Taira, Yuki ^{[1
]}

Shang, Jingwei ^{[1
]}

Tsunoda, Keiichiro ^{[1
]}

Feng, Tian ^{[1
]}

Sasaki, Ryo ^{[1
]}

Liu, Xia ^{[1
]}

Shi, Xiaowen ^{[1
]}

Tadokoro, Koh ^{[1
]}

Nomura, Emi ^{[1
]}

Matsumoto, Namiko ^{[1
]}

Osakada, Yusuke ^{[1
]}

Omote, Yoshio ^{[1
]}

Takemoto, Mami ^{[1
]}

Hishikawa, Nozomi ^{[1
]}

Ohta, Yasuyuki ^{[1
]}

Abe, Koji ^{[1
]}

机构：

[1] Okayama Univ, Dept Neurol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan

来源：

CURRENT NEUROVASCULAR RESEARCH | 2020年 / 17卷 / 03期

关键词：

Ischemic stroke; middle cerebral artery occlusion; rosmarinic acid; polyphenolic complex; anti-inflammation; blood brain barrier; MONOCYTE CHEMOATTRACTANT PROTEIN-1; FOCAL CEREBRAL-ISCHEMIA; ROSMARINUS-OFFICINALIS; OXIDATIVE STRESS; NITRIC-OXIDE; IN-VITRO; STROKE; MOUSE; EXTRACT; EXPRESSION;

D O I：

10.2174/1567202617666200517105727

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Background: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix's effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO) model mice is investigated in this study. Methods: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. Results: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO, **P< 0.01), reduced infarct volume (P-#<0.05), suppressed expression of ionized calcium-binding adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1) (P-###< 0.001), and improved the integrity of BBB (P-<section>< 0.05) at 5 days after tMCAO. Conclusion: The present study provided an evidence of Neumentix's anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice, suggesting that Neumentix could be a potential therapeutic agent for stroke.

引用

页码：286 / 293

页数：8

共 49 条

[1]

Abe K., 1992, Neurological Research, V14, P381

[2]

Inflammation and Stroke: An Overview [J].